Skip to main content

CVRx, Inc. (CVRX)

NASDAQ: CVRX · Delayed Price · USD
15.78
+0.61 (4.02%)
Pre-market:Sep 20, 2021 7:01 AM EDT
15.17
-0.61 (-3.87%)
At close: Sep 17, 4:00 PM
Market Cap292.70M
Revenue (ttm)7.20M
Net Income (ttm)-18.92M
Shares Out19.29M
EPS (ttm)-0.98
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume484,409
Open15.79
Previous Close15.78
Day's Range15.00 - 16.25
52-Week Range14.86 - 29.00
Betan/a
Analystsn/a
Price Target26.67 (+75.8%)
Est. Earnings DateNov 4, 2021

About CVRX

CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Our second-generation product, BAROSTIM NEO, is the first and only commercially available neuromodulation device indicated to improve symptoms for patients with heart failure (“HF”) with reduced Ejection Fraction (“HFrEF”), or systolic HF. BAROSTIM NEO provides Baroreflex Activation Therapy (“BAROSTIM Therapy”) by sending impe...

IndustryMedical Devices
IPO DateJun 30, 2021
CEONadim Yared
Employees63
Stock ExchangeNASDAQ
Ticker SymbolCVRX
Full Company Profile

Financial Performance

In 2020, CVRx's revenue was $6.05 million, a decrease of -3.26% compared to the previous year's $6.26 million. Losses were -$14.11 million, -3.58% less than in 2019.

Financial Statements

News

CVRx Added to Russell 2000® and 3000® Indexes

MINNEAPOLIS, Sept. 17, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and mini...

3 days ago - GlobeNewsWire

CVRx Reports Second Quarter 2021 Financial and Operating Results

Second Quarter 2021 Revenue of $3.1 Million, a 150% Increase Over Prior Year Second Quarter 2021 Revenue of $3.1 Million, a 150% Increase Over Prior Year

1 month ago - GlobeNewsWire

CVRx to Present at the Canaccord Genuity 41st Annual Growth Conference

MINNEAPOLIS, July 29, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive n...

1 month ago - GlobeNewsWire

CVRx to Report Second Quarter 2021 Financial and Operating Results and Host Conference Call

MINNEAPOLIS, July 21, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative and minimally invasive ...

1 month ago - GlobeNewsWire

CVRx Welcomes Veteran Life Science Industry Leader Martha Shadan to its Board of Directors

MINNEAPOLIS, July 12, 2021 (GLOBE NEWSWIRE) -- CVRx , Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative and minimally invasive...

2 months ago - GlobeNewsWire

Treo Ventures Announces the Successful IPO of its Portfolio Company CVRx® (NSDQ: CVRX)

SANTA CLARA, Calif. and DUBLIN, July 6, 2021 /PRNewswire/ -- Treo Ventures portfolio company CVRx, Inc. announced the upsized pricing of its initial public offering on the Nasdaq Global Select Market.

2 months ago - PRNewsWire

CVRx, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Add...

MINNEAPOLIS, July 02, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive n...

2 months ago - GlobeNewsWire

CVRx, Inc. Announces Upsized Pricing of Initial Public Offering

CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and...

2 months ago - GlobeNewswire

A no-brainer: CVRx plots $92M IPO for its neuro-stim implant for heart failure

With a first-of-its-kind FDA approval under its belt, CVRx’s next move is a no-brainer: The brain stimulation device maker has filed for a Nasdaq initial public offering that could rake in up to $105.5 ...

2 months ago - FierceBiotech

CVRx® Announces First Clinical Procedure with a New Ultrasound-Guided Implant Approach, the Latest Advancement in Bar...

CVRx®, developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart...

3 months ago - GlobeNewswire

CVRx IPO Registration Document (S-1)

CVRx, Inc. has filed to go public with an IPO on the NASDAQ.

3 months ago - SEC